DionyMed Provides Update on Filing of Financial Statements for the Period Ended December 31, 2018

TORONTO--(BUSINESS WIRE)-- Further to its press releases dated April 30, 2019 and April 14, 2019, DionyMed Brands Inc. (CSE: DYME) (“DionyMed” or the “Company”) is providing an update with respect to the previously announced delay in the filing of its annual financial statements for the year ended December 31, 2018 and the management cease trade order (the "MCTO") issued by the British Columbia Securities Commission on May 2, 2019. The MCTO was issued in connection with this delay by the Company in filing the annual financial statements, and the related management's discussion and analysis and officer certifications (collectively, the "Annual Filings") beyond the required filing deadline of April 30, 2019.

The Company is working closely with its auditor and continues to expect to file the Annual Filings on or before May 31, 2019. The Company does not anticipate any delay in filing its interim financial statements, management's discussion and analysis, and the related officer certifications for the financial period ended March 31, 2019.

On behalf of the Board,

Edward Fields
Chief Executive Officer

About DionyMed

Founded in 2017, DionyMed is a multi-state cannabis brands platform, supporting cultivators, manufacturers and award-winning brands in the medical and adult-use cannabis markets. DionyMed sells branded products in every category from flower to vape cartridges, concentrates and edibles. DionyMed serves cannabis consumers through retail dispensary distribution and direct-to-consumer fulfillment with its growing portfolio of award-winning brands. Learn more at dionymed.com and follow @DYME_Inc on Twitter and LinkedIn.

Cautionary Statement on Forward-Looking Statements

The information in this document contains certain forward-looking statements with respect to activities of the Company, based on assumptions about future courses of action, including with respect to the filing of the Annual Filings. Although management has a reasonable basis for the conclusions drawn, risk factors and uncertainties may cause actual results to differ materially from those currently anticipated in such statements. In view of these uncertainties we caution readers not to place undue reliance on these forward-looking statements. Statements made in this document are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any statements made herein, except in accordance with applicable securities laws.

Edward Fields, CEO

Peter Kampian, CFO

Phil Carlson / Erika Kay
KCSA Strategic Communications
Phone: (212) 896-1233
Email: pcarlson@kcsa.com / ekay@kcsa.com

Kate Tumino / Brittany Tibaldi
KCSA Strategic Communications
212-896-1252 / 347-487-6794
ktumino@kcsa.com / btibaldi@kcsa.com

Source: DionyMed Brands Inc.